[The dopamine agonist, lisuride, in the therapy of Parkinson disease].
The development of fluctuations in disability are a main problem of the levodopa long-term treatment in Parkinson's disease. The early combination of low doses of levodopa with a dopamine agonist as lisuride improves the symptoms of Parkinson's disease as much as a monotherapy but prevents the development of fluctuations in disability and dyskinesias at the same time.
Madeja
U D
UD
Abteilung Innere Medizin, Schering AG, Berlin.
D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008090:Lisuride / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use
D012642:Selegiline; D007980:Levodopa; D008090:Lisuride
Der Dopamin-Agonist Lisurid in der Therapie des Morbus Parkinson.